Who are Blinatumomab plus Reduced-dose Chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SCT800 and Daratumumab, Cadonilimab (AK104), GST-HG141, BAT8001 for injection, Amivantamab Intravenous, SHR-A2009 monotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/blinatumomab-plus-reduced-dose-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Blinatumomab plus Reduced-dose Chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blinatumomab plus Reduced-dose Chemotherapy (Blinatumomab plus Reduced-dose Chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific monoclonal antibody. Area: Oncology.

phase 2 Bispecific monoclonal antibody CD19 and CD3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Blinatumomab plus Reduced-dose Chemotherapy (Blinatumomab plus Reduced-dose Chemotherapy) — Xianmin Song, MD. Blinatumomab targets CD19 and CD3 on T cells, leading to T cell activation and killing of B cell malignancies.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Blinatumomab plus Reduced-dose Chemotherapy TARGET	Blinatumomab plus Reduced-dose Chemotherapy	Xianmin Song, MD	phase 2	Bispecific monoclonal antibody	CD19 and CD3
SCT800 and Daratumumab	SCT800 and Daratumumab	Institute of Hematology & Blood Diseases Hospital, China	marketed	Bispecific T-cell engager (SCT800); CD38-targeting monoclonal antibody (Daratumumab)	CD19 and CD3 (SCT800); CD38 (Daratumumab)
Cadonilimab (AK104)	Cadonilimab (AK104)	Guangxi Medical University	phase 3	Bispecific monoclonal antibody; dual checkpoint inhibitor	PD-L1 and TIM-3
GST-HG141	GST-HG141	Fujian Akeylink Biotechnology Co., Ltd.	phase 3	Bispecific monoclonal antibody
BAT8001 for injection	BAT8001 for injection	Bio-Thera Solutions	phase 3	Bispecific monoclonal antibody
Amivantamab Intravenous	Amivantamab Intravenous	Janssen Research & Development, LLC	phase 3	Bispecific monoclonal antibody	EGFR and MET
SHR-A2009 monotherapy	SHR-A2009 monotherapy	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Bispecific monoclonal antibody

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific monoclonal antibody class)

Akeso · 1 drug in this class
Bio-Thera Solutions · 1 drug in this class
Fujian Akeylink Biotechnology Co., Ltd. · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
Shanghai JMT-Bio Inc. · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class
Xianmin Song, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Blinatumomab plus Reduced-dose Chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/blinatumomab-plus-reduced-dose-chemotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab